COSMOCOL HALF

Posology Chronic constipation A course of treatment for constipation does not normally exceed two weeks, although this can be repeated if required. As for all laxatives. Prolonged use is not usually recommended. Extended use may be necessary in the care of patients with severe chronic or resistant constipation, secondary to multiple sclerosis or Parkinson’s disease, or induced by regular constipating medication, in particular opioids and antimuscarinics.

Adults, Adolescents and the Elderly 2-6 sachets daily in divided doses, according to individual response. For extended use, dose can be adjusted down to 2-4 sachets daily. Children (below 12 years old) Not recommended. Alternative products are available for children.

Faecal impaction Adults, Adolescents and the Elderly A course of treatment for faecal impaction does not normally exceed 3 days. Dosage is 16 sachets daily, all of which should be consumed within a 6-hour period. The above dosage regimen should be stopped once disimpaction has occurred.

An indicator of disimpaction is the passage of a large volume of stools. After disimpaction, it is recommended that the patient follows an appropriate bowel management programme to prevent reimpaction. Children (below 12 years of age) Not recommended.

Alternative products are available for children. Patients with impaired cardiovascular function For the treatment of faecal impaction, the dose should be divided so that no more than four sachets are taken in any one hour. Patients with renal insufficiency No dosage change is necessary for the treatment of either constipation or faecal impaction.

5 ml (quarter of a glass) of water. For use in faecal impaction the correct number of sachets can be reconstituted in advance and kept covered and refrigerated for up to 6 hours. For example, dissolved 16 sachets in one litre of water for the treatment of faecal impaction.

Reactions related to the gastrointestinal tract occur most commonly. These reactions may occur as a consequence of expansion of the contents of the gastrointestinal tract, and an increase in motility due to the pharmacologic effects of Compound Macrogol Oral Powder Sugar Free.

Mild diarrhoea usually responds to dose reduction. The frequency of the adverse effects is not known as it cannot be estimated from the available data. System Organ Class Adverse Event Immune system disorders Allergic reactions, including anaphylactic reactions, dyspnoea and skin reactions (see below).

Skin and subcutaneous tissue disorders Allergic skin reactions including angioedema, urticaria, pruritus, rash, erythema. Metabolism and nutrition disorders Electrolyte disturbances, particularly hyperkalaemia and hypokalaemia. Nervous system disorders Headache.

Gastrointestinal disorders Abdominal pain, diarrhoea, vomiting, nausea, dyspepsia, abdominal distension, borborygmi, flatulence, anal discomfort. General disorders and administration site conditions Peripheral oedema. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.

It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

The fluid content of CosmoCol Half when re-constituted with water does not replace regular fluid intake and adequate fluid intake must be maintained. Confirm diagnosis of faecal impaction / faecal loading of the rectum by physical or radiological examination of the abdomen and rectum.

g. oedema, shortness of breath, increasing fatigue, dehydration and cardiac failure. If these symptoms occur, stop treatment with CosmoCol Half immediately. Measure electrolytes and treat any abnormality with appropriate counter measures.

When using high doses of this medicine to treat faecal impaction, use caution in patients with impaired gag reflex, reflux oesophagitis or reduced levels of consciousness. In patients with swallowing problems, who need the addition of a thickener to solutions to enhance an appropriate intake, interactions should be considered, see section

Intestinal perforation or obstruction due to structural or functional disorder of the gut wall, ileus, severe inflammatory bowel diseases such as Crohn's disease, ulcerative colitis and toxic megacolon. 1.